• 1
    Kandiah DA, Krilis SA. Laboratory detection of antiphospholipid antibodies. Lupus 1996; 5: 1602.
  • 2
    Shapiro SS, Thiagarajan P. Lupus anticoagulants. Prog Haemost Thromb 1982; 6: 26385.
  • 3
    Exner T, Triplett DA, Taberner D, Machin SJ. Guidlines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 3202.
  • 4
    Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995; 74: 118590.
  • 5
    Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 12114.
  • 6
    Loizou S, McCrea JD, Rudge A, Reynolds. R, Boyle CC, Harris EN. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 73845.
  • 7
    Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 62932.
  • 8
    Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 287892.
  • 9
    Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 11004.
  • 10
    Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, De Groot PhG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemost 1992; 67: 499502.
  • 11
    Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibition by β2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost 1993; 70: 3425.
  • 12
    Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. ‘Anticardiolipin’ autoantibodies recognize β2-glycoprotein I in the absence of phospholipid: importance of Ag density and bivalent binding. J Immunol 1995; 154: 95460.
  • 13
    Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 7986.
  • 14
    Willems GM, Janssen MP, Pelsers MAL, Comfurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 1383342.
  • 15
    Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 1997; 99: 22608.
  • 16
    Simmelink MJA, Horbach DA, Derksen RHWM, Meijers JCM, Bevers EM, Willems GM, De Groot PG. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113: 6219.
  • 17
    Horbach DA, Van Oort E, Donders RCJM, Derksen RHWM, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus – comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 91624.
  • 18
    Wahl DG, Guillemin F, De Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus – a meta-analysis. Lupus 1997; 6: 46773.
  • 19
    Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I- dependent antiphospholipid antibodies. Blood 1995; 86: 61723.
  • 20
    Swadzba J, Declerck LS, Stevens WJ, Bridts CH, Van Cotthem KA, Musial J, Jankowski M, Szczeklik A. Anticardiolipin, anti-β2-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulants in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997; 24: 17105.
  • 21
    D'Angelo A, Safa O, Crippa L, Garlando A, Sabbadini MG, D'Angelo SV. Relationship of lupus anticoagulant, anticardiolipin, anti-β1-GPI and anti-prothrombin autoantibodies with history of thrombosis in patients with the clinical suspicion of APA syndrome. Thromb Haemost 1997; 78: 9678.
  • 22
    Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 214957.
  • 23
    Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update, on behalf of the Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1995; 74: 118590.
  • 24
    Fujikawa K, Thompson AR, Legaz ME, Meyer RG, Davie EW. Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry 1973; 12: 493845.
  • 25
    Arnout J, Vanrusselt M, Wittevrongel C, Vermylen J. Monoclonal antibodies against beta-2-glycoprotein I. Use as reference material for lupus anticoagulant tests. Thromb Haemost 1998; 79: 9558.
  • 26
    Arnout J, Vanrusselt M, Nevens C, Smans K, Wittevrongel C, Vermylen J. Some murine monoclonal antibodies against human prothrombin have lupus anticoagulant activity. Thromb Haemost 1999; 82(Suppl.): 65.
  • 27
    Brunner J, Skrabal P, Hauser H. Single bilayer vesicles prepared without sonication. Physio-chemical properties. Biochim Biophys Acta 1976; 455: 32231.
  • 28
    Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 4946.
  • 29
    Pengo V, Thiagarajan P, Shapiro SS, Heine MJ. Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 1987; 70: 6976.
  • 30
    Horbach DA, Van Oort E, Tempelman MJ, Derksen RHWM, De Groot PhG. The prevalence of a non-phospholipid-binding form of β2-glycoprotein I in human plasma. Consequences for the development of anti-β2-glycoprotein I-antibodies. Thromb Haemost 1998; 80: 7918.
  • 31
    Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe. an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81: 92934.
  • 32
    Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from thre surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation. Thromb Haemost 1997; 77: 9347.
  • 33
    Schousboe I. Purification, characterization and identification of an agglutinin in human serum. Biochim Biophys Acta 1979; 579: 396408.
  • 34
    Brighton TA, Dai YP, Hogg PJ, Chesterman CN. Microheterogeneity of β2-glycoprotein I. implications for binding to anionic phospholipids. Biochem J 1999; 340: 5967.
  • 35
    Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 20828.
  • 36
    Hoshino M, Hagihara Y, Nishii I, Yamazaki T, Kato H, Goto Y. Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance. J Mol Biol 1998; 304: 92739.
  • 37
    Mehdi H, Naqvi A, Kamboh MI. A hydrophobic sequence at position 313–316 (Leu-Ala-Phe-Trp) in the fifth domain of apolipoprotein H (β2-glycoprotein I) is crucial for cardiolipin binding. Eur J Biochem 2000; 267: 17706.
  • 38
    Arnout J. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome. Verh K Acad Geneeskd Belg 2000; 62: 35372.
  • 39
    Hagihara Y, Goto Y, Kato H, Yoshimura T. Role of the N- and C-terminal domains of bovine β2-glycoprotein I in its interaction with cardiolipin. J Biochem (Tokyo) 1995; 118: 12936.
  • 40
    Cuypers PA, Corsel JW, Janssen MP, Kop JM, Hermens WT, Hemker HC. The adsorption of prothrombin to phosphatidylserine multilayers quantitated by ellipsometry. J Biol Chem 1983; 258: 242631.
  • 41
    Lu YF, Nelsestuen GL. Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: Implications for protein-membrane contact. Biochemistry 1996; 35: 8193200.
  • 42
    McDonald JF, Shah AM, Schwalbe RA, Kisiel W, Dahlback B, Nelsestuen GL. Comparison of naturally occuring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36: 51207.
  • 43
    Ellison EH, Castellino FJ. Adsorption of vitamin K-dependent blood coagulation proteins to spread phospholipid monolayers as determined from combined measurements of the surface pressure and surface protein concentration. Biochemistry 1998; 37: 79978003.
  • 44
    Govers-Riemslag JWP, Johnsen L, Petrovan RJ, Rosing J, Tans G. A kinetic assay to determine prothrombin binding to membranes. Thromb Res 1998; 92: 23947.
  • 45
    Mann KG, Elion J, Butkowski RJ, Downing M, Nesheim ME. Prothrombin. In: Anonymous Blood Clotting. New York, Academic Press Inc., 1981: 286302.
  • 46
    Mayer LD, Nelsestuen GL, Brockman HL. Prothrombin association with phospholipid monolayers. Biochemistry 1983; 22: 31642321.
  • 47
    Mann KG, Lawson JH. The role of the membrane in the expression of the vitamin K-dependent enzymes. Arch Pathol Lab Med 1992; 116: 13306.